Jonathan R Dry

Summary

Affiliation: AstraZeneca R and D

Publications

  1. pmc Looking beyond the cancer cell for effective drug combinations
    Jonathan R Dry
    Oncology Innovative Medicines and Early Development, AstraZeneca, R and D Boston, Waltham, MA, 02451, USA
    Genome Med 8:125. 2016
  2. pmc Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)
    Jonathan R Dry
    Cancer Bioscience, DECS, and Clinical Biomarker Group, AstraZeneca R and D, Alderley Park, Macclesfield, United Kingdom
    Cancer Res 70:2264-73. 2010

Detail Information

Publications2

  1. pmc Looking beyond the cancer cell for effective drug combinations
    Jonathan R Dry
    Oncology Innovative Medicines and Early Development, AstraZeneca, R and D Boston, Waltham, MA, 02451, USA
    Genome Med 8:125. 2016
    ..In this Opinion article, we discuss preliminary work in this area and the needs-in terms of both computational and data requirements-that will truly empower such combinations...
  2. pmc Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)
    Jonathan R Dry
    Cancer Bioscience, DECS, and Clinical Biomarker Group, AstraZeneca R and D, Alderley Park, Macclesfield, United Kingdom
    Cancer Res 70:2264-73. 2010
    ..These signatures offer useful tools for the study of MEK biology and clinical application of MEK inhibitors, and the novel approaches taken may benefit other targeted therapies...